Neural Therapeutics - How do we prevent people getting addicted to opioids? | News Direct

Neural Therapeutics - How do we prevent people getting addicted to opioids?

Neural Therapeutics Inc.
News release by Neural Therapeutics Inc.

facebook icon linkedin icon twitter icon pinterest icon email icon London, UK | May 20, 2024 09:00 AM Eastern Daylight Time


Neural Therapeutics CEO Ian Campbell is answering some of the questions raised by Scientific Advisor Professor David Nutt's presentation on the potentially revolutionary untapped effects of psychedelic medicine.

Today's questions asks: "The opioid crisis has touched every sector of society and shows no sign of stopping. How do we prevent more people from becoming addicted?"

He emphasised that contrary to common concerns, the substances developed by the company have not shown addictive properties in clinical trials. Campbell highlighted that there is no evidence of withdrawal symptoms in patients. Moreover, ongoing scientific work supports the effectiveness of these substances in treating individuals with substance use disorders.

The presentation focused on what Professor Nutt describes as the utility of psychedelic compounds and their potential to transform the treatment of mental illness.

To watch the full presentation, click here: 

Neural Therapeutics is a drug-discovery company focusing on plant-based active substances with the goal of delivering beneficial, over-the-counter dietary supplements and psychedelic-based therapeutic medicines to treat serious mental ailments where no significant treatment is available today.


Contact Details


Proactive United States


+1 347-449-0879

project media